Novel Insight in Idiopathic Normal Pressure Hydrocephalus (iNPH) Biomarker Discovery in CSF. 2021

Enrica Torretta, and Beatrice Arosio, and Pietro Barbacini, and Daniele Capitanio, and Paolo Dionigi Rossi, and Manuela Moriggi, and Mario Clerici, and Daniela Mari, and Matteo Cesari, and Cecilia Gelfi
IRCCS Istituto Ortopedico Galeazzi, Via Galeazzi 4, 20161 Milan, Italy.

Idiopathic normal pressure hydrocephalus (iNPH) is a potentially reversible neurological disease, causing motor and cognitive dysfunction and dementia. iNPH and Alzheimer's disease (AD) share similar molecular characteristics, including amyloid deposition, t-tau and p-tau dysregulation; however, the disease is under-diagnosed and under-treated. The aim was to identify a panel of sphingolipids and proteins in CSF to diagnose iNPH at onset compared to aged subjects with cognitive integrity (C) and AD patients by adopting multiple reaction monitoring mass spectrometry (MRM-MS) for sphingolipid quantitative assessment and advanced high-resolution liquid chromatography-tandem mass spectrometry (LC-MS/MS) for proteomic analysis. The results indicated that iNPH are characterized by an increase in very long chains Cer C22:0, Cer C24:0 and Cer C24:1 and of acute-phase proteins, immunoglobulins and complement component fragments. Proteins involved in synaptic signaling, axogenesis, including BACE1, APP, SEZ6L and SEZ6L2; secretory proteins (CHGA, SCG3 and VGF); glycosylation proteins (POMGNT1 and DAG1); and proteins involved in lipid metabolism (APOH and LCAT) were statistically lower in iNPH. In conclusion, at the disease onset, several factors contribute to maintaining cell homeostasis, and the protective role of very long chains sphingolipids counteract overexpression of amyloidogenic and neurotoxic proteins. Monitoring specific very long chain Cers will improve the early diagnosis and can promote patient follow-up.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009419 Nerve Tissue Proteins Proteins, Nerve Tissue,Tissue Proteins, Nerve
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006850 Hydrocephalus, Normal Pressure A form of compensated hydrocephalus characterized clinically by a slowly progressive gait disorder (see GAIT DISORDERS, NEUROLOGIC), progressive intellectual decline, and URINARY INCONTINENCE. Spinal fluid pressure tends to be in the high normal range. This condition may result from processes which interfere with the absorption of CSF including SUBARACHNOID HEMORRHAGE, chronic MENINGITIS, and other conditions. (From Adams et al., Principles of Neurology, 6th ed, pp631-3) Hakim Syndrome,Normal Pressure Hydrocephalus,Hakim's Syndrome,Hydrocephalus, Normal-Pressure,NPH (Normal Pressure Hydrocephalus),Hakim Syndromes,Hakim's Syndromes,Hakims Syndrome,NPHs (Normal Pressure Hydrocephalus),Syndrome, Hakim,Syndrome, Hakim's,Syndromes, Hakim,Syndromes, Hakim's
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D013107 Sphingolipids A class of membrane lipids that have a polar head and two nonpolar tails. They are composed of one molecule of the long-chain amino alcohol sphingosine (4-sphingenine) or one of its derivatives, one molecule of a long-chain acid, a polar head alcohol and sometimes phosphoric acid in diester linkage at the polar head group. (Lehninger et al, Principles of Biochemistry, 2nd ed) Lysosphingolipids,Sphingolipid
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune

Related Publications

Enrica Torretta, and Beatrice Arosio, and Pietro Barbacini, and Daniele Capitanio, and Paolo Dionigi Rossi, and Manuela Moriggi, and Mario Clerici, and Daniela Mari, and Matteo Cesari, and Cecilia Gelfi
September 2016, Journal of the neurological sciences,
Enrica Torretta, and Beatrice Arosio, and Pietro Barbacini, and Daniele Capitanio, and Paolo Dionigi Rossi, and Manuela Moriggi, and Mario Clerici, and Daniela Mari, and Matteo Cesari, and Cecilia Gelfi
June 2022, Journal of personalized medicine,
Enrica Torretta, and Beatrice Arosio, and Pietro Barbacini, and Daniele Capitanio, and Paolo Dionigi Rossi, and Manuela Moriggi, and Mario Clerici, and Daniela Mari, and Matteo Cesari, and Cecilia Gelfi
June 2020, British journal of neurosurgery,
Enrica Torretta, and Beatrice Arosio, and Pietro Barbacini, and Daniele Capitanio, and Paolo Dionigi Rossi, and Manuela Moriggi, and Mario Clerici, and Daniela Mari, and Matteo Cesari, and Cecilia Gelfi
July 2015, The Cochrane database of systematic reviews,
Enrica Torretta, and Beatrice Arosio, and Pietro Barbacini, and Daniele Capitanio, and Paolo Dionigi Rossi, and Manuela Moriggi, and Mario Clerici, and Daniela Mari, and Matteo Cesari, and Cecilia Gelfi
January 2020, PloS one,
Enrica Torretta, and Beatrice Arosio, and Pietro Barbacini, and Daniele Capitanio, and Paolo Dionigi Rossi, and Manuela Moriggi, and Mario Clerici, and Daniela Mari, and Matteo Cesari, and Cecilia Gelfi
November 2010, Rinsho shinkeigaku = Clinical neurology,
Enrica Torretta, and Beatrice Arosio, and Pietro Barbacini, and Daniele Capitanio, and Paolo Dionigi Rossi, and Manuela Moriggi, and Mario Clerici, and Daniela Mari, and Matteo Cesari, and Cecilia Gelfi
February 2024, Biomedical physics & engineering express,
Enrica Torretta, and Beatrice Arosio, and Pietro Barbacini, and Daniele Capitanio, and Paolo Dionigi Rossi, and Manuela Moriggi, and Mario Clerici, and Daniela Mari, and Matteo Cesari, and Cecilia Gelfi
January 2012, Internal medicine (Tokyo, Japan),
Enrica Torretta, and Beatrice Arosio, and Pietro Barbacini, and Daniele Capitanio, and Paolo Dionigi Rossi, and Manuela Moriggi, and Mario Clerici, and Daniela Mari, and Matteo Cesari, and Cecilia Gelfi
January 2022, Frontiers in neurology,
Enrica Torretta, and Beatrice Arosio, and Pietro Barbacini, and Daniele Capitanio, and Paolo Dionigi Rossi, and Manuela Moriggi, and Mario Clerici, and Daniela Mari, and Matteo Cesari, and Cecilia Gelfi
January 2021, Neurology India,
Copied contents to your clipboard!